- Report
- April 2025
- 150 Pages
Global
From €4409EUR$4,850USD£3,790GBP
- Report
- July 2025
- 100 Pages
Global
From €3500EUR$4,125USD£3,115GBP
- Report
- April 2025
- 21 Pages
Global
From €16357EUR$17,995USD£14,064GBP
- Report
- May 2023
- 79 Pages
Global
From €3500EUR$4,125USD£3,115GBP
- Report
- May 2023
- 109 Pages
Global
From €3500EUR$4,125USD£3,115GBP
- Report
- January 2025
- 132 Pages
Global
From €864EUR$950USD£742GBP
- Report
- January 2025
- 132 Pages
Global
From €864EUR$950USD£742GBP
Chronic Obstructive Pulmonary Disease (COPD) is a progressive lung disease that affects millions of people worldwide. It is characterized by difficulty breathing, coughing, and wheezing. COPD is typically treated with a combination of medications, including bronchodilators, inhaled corticosteroids, and antibiotics. The COPD drug market is a subset of the larger respiratory drug market, which includes drugs used to treat asthma, allergies, and other respiratory conditions.
The COPD drug market is highly competitive, with a variety of companies offering different types of medications. Some of the major players in the market include GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim, Novartis, and Merck. These companies offer a range of COPD medications, including bronchodilators, inhaled corticosteroids, and antibiotics. Other companies, such as Teva Pharmaceuticals and Mylan, also offer generic versions of these medications. Show Less Read more